Drugs / Alpha-Gal Glycosphingolipid
Alpha-Gal Glycosphingolipid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00668382 | Jul 2007 → Jul 2011 | metastatic neoplasm | University of Massachusetts, Worcester | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-Gal Glycosphingolipid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00668382 ↗ |
| Known as | alpha gal glycolipid | “The primary treatment is a single intratumoral injection of alpha gal glycolipid.” NCT00668382 ↗ |
| Known as | GSL alpha-GAL | “This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with...” NCT00668382 ↗ |